VitaNova Life Sciences Corp
VitaNova Life Sciences Corp
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | 2023-04-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | - | - | - | 1 | 0 | 0 | 0 | |||||
Other Receivables Net Current | - | - | - | - | - | - | - | - | 0 | - | - | - | |||||
Cash | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | - | - | - | 0 | |||||
Accounts Receivable Net Current | 1 | 1 | 1 | 1 | 0 | 0 | - | 0 | - | - | - | - | |||||
Nontrade Receivables Current | - | - | - | - | - | - | - | 0 | - | - | - | 0 | |||||
Prepaid Expense Current | - | 0 | 0 | - | - | - | - | - | - | - | - | - | |||||
Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | |||||
Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | |||||
Assets Current | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |||||
Assets | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | - | 0 | |||||
Accounts Payable And Other Accrued Liabilities Cur… | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Accounts Payable Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Deferred Revenue Current | - | 0 | 0 | - | - | - | - | - | - | - | - | - | |||||
Other Liabilities Current | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | |||||
Liabilities Current | |||||||||||||||||
Accounts Payable And Accrued Liabilities Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | |||||
Accrued Liabilities Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Taxes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | |||||
Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Value | 0 | - | - | - | - | - | - | - | - | - | - | - | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |||||
Retained Earnings Accumulated Deficit | 1 | 1 | 1 | 1 | 0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | |||||
Stockholders Equity | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | -0 | -0 | -0 | |||||
Liabilities And Stockholders Equity | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | - | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | - | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | |||||
Common Stock Shares Issued | - | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 23 | 23 | 23 | |||||
Shares Outstanding | - | 8 | 8 | 8 | 8 | 8 | 8 | 25 | 6 | 6 | 6 | 6 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.61% | 794.44% | 794.44% | 0.00% | 0.00% | 0.00% | 0.00% | -71.43% | -71.43% | - | - | - |
| 2025 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 677.78% |
| 2024 | 0.00% | -80.00% | -80.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -66.17% | -66.17% | -66.17% |
| 2023 | - | - | - | - | - | - | - | - | - | -1.00% | -1.00% | -1.00% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | 2023-04-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 5.05 | 5.33 | 5.90 | 6.49 | 6.21 | 5.62 | 6.02 | 8.71 | 10.31 | - | - | 0.13 | |||||
| Quick Ratio | 4.76 | 5.29 | 5.85 | 6.36 | 5.33 | 4.27 | 4.95 | 7.74 | 10.31 | - | - | 0.13 | |||||
| Working Capital | 1.85M | 1.90M | 1.86M | 1.91M | 1.11M | 1.03M | 1.00M | 1.06M | 870.78K | - | - | -59.22K | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.25 | 0.23 | 0.20 | 0.18 | 0.19 | 0.22 | 0.20 | 0.13 | 0.11 | -1.00 | -1.00 | -1.15 | |||||
| Interest Coverage TTM | 733.61 | 509.22 | 260.96 | 258.08 | 122.10 | 120.38 | - | - | - | - | - | - | |||||
| Debt Ratio | 0.20 | 0.19 | 0.17 | 0.15 | 0.16 | 0.18 | 0.17 | 0.11 | 0.10 | - | - | 7.78 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 1.76 | 1.55 | 1.54 | 1.54 | 1.10 | 0.77 | 0.57 | 0.95 | 0.06 | - | - | 2.39 | |||||
| Days Sales Outstanding TTM | 60.48 | 61.45 | 139.31 | 173.71 | 15.73 | 21.68 | - | - | - | - | - | - | |||||
| Receivables Turnover TTM | 6.03 | 5.94 | 2.62 | 2.10 | 23.21 | 16.83 | - | - | - | - | - | - | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | 0.09 | 0.10 | 0.10 | 0.10 | 0.03 | 0.02 | 0.01 | 0.01 | -0.01 | -0.01 | -0.01 | -0.00 | |||||
| Free Cash Flow Per Share TTM | 0.10 | 0.14 | 0.12 | 0.02 | -0.06 | -0.10 | -0.10 | -0.04 | -0.03 | -0.01 | -0.01 | -0.00 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 56.46% | 60.03% | 59.13% | 59.19% | 61.42% | 62.47% | - | - | - | - | - | - | |||||
| Operating Profit Margin TTM | 36.02% | 43.42% | 44.25% | 43.68% | 28.62% | 26.34% | 27.16% | 36.03% | -108.04% | -476.65% | -220.03% | -63.76% | |||||
| Net Profit Margin TTM | 23.34% | 30.90% | 32.35% | 31.96% | 17.42% | 15.58% | 16.18% | 24.68% | -108.04% | -476.65% | -220.03% | -63.76% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 154.79% | 187.51% | 291.29% | 366.47% | 4,207.58% | 7,371.45% | 2,852.92% | 1,401.83% | -63.63% | -87.00% | -82.96% | -68.33% | |||||
| Net Income Growth (1Y) | 241.44% | 470.26% | 682.21% | 503.94% | -794.47% | -344.18% | -317.16% | -681.44% | -32.61% | 371.03% | 6,674.83% | -117.34% | |||||
| EPS Growth (1Y) | 241.44% | 470.26% | 682.21% | 670.98% | -606.38% | -271.95% | -252.93% | -420.74% | -34.91% | 371.03% | 6,674.83% | -117.34% | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 865.23K | 1.16M | 960.59K | 192.77K | -477.55K | -836.98K | -853.73K | -375.88K | -186.98K | -64.60K | -51.30K | -18.38K | |||||
| Net Debt | -1.17M | -1.26M | -1.05M | -13.21K | -405.17K | -222.80K | -141.64K | -593.04K | -808.36K | 0.00 | 0.00 | -8.73K | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
VitaNova Life Sciences Corp (VNOV) — SEC Financial Statements & Analysis
VitaNova Life Sciences Corp (VNOV) is a wholesale-apparel, piece goods & notions company, incorporated in NV. VitaNova Life Sciences Corp trades on OTC as: VNOV. Based on its latest SEC filing (Form 10-Q, period ending 2026-01-31), VitaNova Life Sciences Corp reported a 154.79% year-over-year revenue growth, a Gross Profit Margin of 56.46% (TTM), a Debt-to-Equity ratio of 0.25x. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 154.79%
- Gross Profit Margin TTM
- 56.46%
- Debt To Equity
- 0.25x
Data as of 2026-01-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is VitaNova Life Sciences Corp in?
VitaNova Life Sciences Corp (VNOV) operates in the Wholesale-Apparel, Piece Goods & Notions industry.
What exchange does VNOV trade on?
VitaNova Life Sciences Corp (VNOV) trades on the OTC.
Where is VitaNova Life Sciences Corp incorporated?
VitaNova Life Sciences Corp is incorporated in NV.